Amir Nashat
Amir Nashat's purchase track record
How the stock did after each of Amir Nashat's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2025 | CAMP | $2.00M | +116.2% | +93.5% | +1.3% |
| 10/15/2024 | CAMP | $10.00M | -65.2% | -82.8% | -7.2% |
| 6/22/2022 | SRRK | $5.87M | +59.0% | +49.5% | +3.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Transaction History
| CAMP | ▲ Buy | Open Market | 1,221,721 | $1.9M | 9/11/2025 | View on chart |
| CAMP | ▲ Buy | Open Market | 85,468 | $131K | 9/11/2025 | View on chart |
| CAMP | ▼ Sell | Other | 24,745 | — | 10/15/2024 | View on chart |
| CAMP | ▲ Buy | Open Market | 909,090 | $10.0M | 10/15/2024 | View on chart |
| CAMP | ▼ Sell | Other | 1,250,061 | — | 10/15/2024 | View on chart |
| CAMP | ▼ Sell | Other | 87,448 | — | 10/15/2024 | View on chart |
| CAMP | ▼ Sell | Other | 353,718 | — | 10/15/2024 | View on chart |
| SRRK | ▼ Sell | Other | 472,394 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 98,257 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 98,257 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 13,096 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 27,606 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 37 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 322 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 276 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Other | 276 | $0 | 5/9/2024 | View on chart |
| SRRK | ▼ Sell | Gift | 21,333 | $0 | 12/27/2023 | View on chart |
| SRRK | ▼ Sell | Other | 944,789 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 196,520 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 196,520 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 26,192 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 55,211 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 643 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 548 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 548 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 73 | $0 | 12/13/2023 | View on chart |
| SRRK | ▼ Sell | Other | 472,394 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 98,261 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 98,261 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 13,096 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 27,606 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 322 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 276 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 276 | $0 | 11/20/2023 | View on chart |
| SRRK | ▼ Sell | Other | 37 | $0 | 11/20/2023 | View on chart |
| SRRK | ▲ Buy | Open Market | 1,131,850 | $5.5M | 6/22/2022 | View on chart |
| SRRK | ▲ Buy | Open Market | 66,142 | $324K | 6/22/2022 | View on chart |
| SRRK | ▼ Sell | Other | 267,631 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 55,667 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 55,667 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 7,420 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 15,640 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 182 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 160 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 160 | $0 | 11/17/2021 | View on chart |
| SRRK | ▼ Sell | Other | 21 | $0 | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.